Climb Bio, Inc. (CLYM)
9.16
-0.12
(-1.29%)
USD |
NASDAQ |
Nov 20, 10:35
Climb Bio Cash from Operations (Quarterly) : -12.00M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -12.00M |
| June 30, 2026 | -10.55M |
| March 31, 2026 | -14.38M |
| December 31, 2025 | -15.64M |
| September 30, 2025 | -12.14M |
| June 30, 2025 | -11.15M |
| March 31, 2025 | -15.43M |
| December 31, 2024 | -5.521M |
| September 30, 2024 | -7.555M |
| June 30, 2024 | -0.667M |
| March 31, 2024 | -1.819M |
| December 31, 2023 | -0.947M |
| September 30, 2023 | 3.49M |
| June 30, 2023 | -7.965M |
| Date | Value |
|---|---|
| March 31, 2023 | -15.18M |
| December 31, 2022 | -8.449M |
| September 30, 2022 | -4.175M |
| June 30, 2022 | -13.97M |
| March 31, 2022 | -10.78M |
| December 31, 2021 | -7.884M |
| September 30, 2021 | -12.97M |
| June 30, 2021 | -8.481M |
| March 31, 2021 | -6.74M |
| December 31, 2020 | |
| September 30, 2020 | -2.381M |
| June 30, 2020 | -3.768M |
| March 31, 2020 | -2.325M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | -46.83M |
| Cullinan Therapeutics, Inc. | -43.08M |
| Q32 Bio, Inc. | -4.418M |
| Oncolytics Biotech, Inc. | -6.754M |
| Sangamo Therapeutics, Inc. | -19.28M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 6.40M |
| Cash from Financing (Quarterly) | 1.224M |
| Free Cash Flow | -53.64M |
| Free Cash Flow Per Share (Quarterly) | -0.1602 |
| Free Cash Flow to Equity (Quarterly) | -12.57M |
| Free Cash Flow to Firm (Quarterly) | -12.82M |
| Free Cash Flow Yield | -10.14% |